Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Loprazolam is a short-acting imidazobenzodiazepine used primarily for the short-term treatment of insomnia, including difficulty falling asleep and frequent nocturnal awakenings. It acts as a positive allosteric modulator of the Gamma aminobutyric acid type A receptor (GABA-A receptor) complex by binding to the benzodiazepine site on alpha subunit-containing GABA-A receptors, enhancing the inhibitory effect of GABA neurotransmission. This results in sedative, hypnotic, anxiolytic, anticonvulsant, amnesic, and muscle relaxant properties. Loprazolam is recommended only for short-term use due to risks such as dependence and withdrawal symptoms. It is not FDA-approved but has been marketed in several countries under various brand names[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on loprazolam.